Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Starbucks Corporation (SBUX), Celgene Corporation (CELG), LinkedIn Corp (LNKD): Top 10 Performing Large Cap Stocks Through First Half of 2013

Page 1 of 2

Starbucks Corporation (NASDAQ:SBUX)As the first half of 2013 ends, let’s look at the year-to-date top performing (and profitable) large cap stocks. Our goal is to identify some winners (and/or their peers) that look like winners going forward.

There are 557 large cap stocks (market caps of $10 billion plus) in the finviz.com universe. I narrowed these down to those with a positive P/E (profitable over trailing twelve months), of which there are 492. Had I not put that speed bump in place, electric vehicle maker Tesla Motors Inc (NASDAQ:TSLA) would have crossed the finish line first, with a 222% return.

Top 10 performing profitable large caps

Company YTD Return (%) P/E Fwd. P/E 5-Yr PEG EPS growth this yr (%) EPS growth next yr (%) ROE (%) D/E
1. Netflix 132.2 522 68.0 8.0 (93) 121 3.3 0.86
2. Sony 89.3 39.9 14.9 0.9 109 204 4.0 0.54
3. Green Mountain Coffee Roasters 78.6 28.4 20.4 1.2 74.0 14.6 17.8 0.15
4. Delta Air Lines 57.5 17.3 6.0 0.3 17.8 14.6 (67.9) N/A
5. LinkedIn 57.3 685 84.0 2.0 46.2 43.9 4.8 0
6. CME Group 53.1 29.3 20.8 1.8 (50.3) 15.8 4.1 0.13
7. Hertz 52.2 36.1 10.0 0.4 35.0 30.6 15.1 8.0
8. Life Technologies 51.0 31.4 16.0 1.8 17.1 9.9 8.9 0.51
9. Celgene 50.9 34.9 16.5 0.9 15.8 20.5 24.8 0.56
10. Ryanair 49.5 19.4 14.9 1.2 3.5 15.8 17.0 1.1

Yahoo! Finance & finviz.com; D/E is debt/equity; data to June 27.

Just because I’m not highlighting a stock doesn’t mean it doesn’t look attractive going forward.

Coffee: an attractive space

In addition to coffee being nearly recession-proof, there’s another good reason to add a coffee player to your portfolio: Green coffee bean prices are at a nearly four-year low, which should continue to give a nice profit boost to large buyers of the commodity. That’s assuming they don’t pass that cost-savings through to consumers, and — other than select packaged coffee producers, such as JM Smucker that’s not been in their game plans. In fact, Starbucks Corporation (NASDAQ:SBUX) just increased prices last week.

In addition to Starbucks Corporation (NASDAQ:SBUX), single-serve king Green Mountain Coffee Roasters, which produces the Keurig and Vue machines, and Dunkin Brands Group Inc (NASDAQ:DNKN) should benefit. Dunkin Brands Group Inc (NASDAQ:DNKN)’ is an East Coast-rooted chain, traditionally focused on coffee and donuts, that’s now expanding to the U.S. West.

Some basic metrics:

Company YTD Return (%) P/E Fwd. P/E 5-Yr PEG EPS growth this yr (%) EPS growth next yr (%) Operating Margin (ttm) Profit Margin (ttm) ROE (%) D/E
Green Mountain 78.6 28.4 20.4 1.2 74.0 14.6 16.1 9.7 17.8 0.15
Starbucks 23.4 33.4 25.0 1.6 10.5 20.4 14.1 10.8 29.0 0.10
Dunkin’ Brands 31.4 46.1 23.9 1.8 166 18.4 39.2 15.9 19.2 5.4

Yahoo! Finance & finviz

Let’s get this one out of the way: Dunkin Brands Group Inc (NASDAQ:DNKN)’ is a pass for now. With the exception of its margins (which will likely come down as it offers more food items), its numbers are uninspiring. It’s much smaller than Starbucks Corporation (NASDAQ:SBUX) — $4.6 billion market cap to Starbucks Corporation (NASDAQ:SBUX)‘ $49.2 billion — yet its projected EPS growth for next year is slightly less than Starbucks’. And, while debt is cheap these days, it’s a negative that it’s leveraged to the hilt (5.4 debt/equity).

Starbucks Corporation (NASDAQ:SBUX) makes the best long-term “core holding,” in my opinion. Granted, it might not be able to outperform to the same degree as Green Mountain over the shorter-term. However, it’s a time-tested leader, and a good match for long-term investors who don’t want to concern themselves with some of the potential drawbacks of Green Mountain, namely the ever-present threat of its K-Cups’ margins being squeezed by increasing competition. Starbucks Corporation (NASDAQ:SBUX)‘ ROE says it all: The company is very efficient at using shareholders’ money to generate profit.

Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ:CELG) is a $49.8 billion market cap biotech company focused on treatments for cancer and immune-inflammatory related diseases.

Its drugs include Revlimid, Thalomid, Vidaza, Abraxane, Isodax, and Pomalyst. Abraxane is used to treat breast and lung cancers, while the others treat various blood cancers. Revlimid, the world’s best-selling multiple myeloma drug, is its blockbuster — accounting for 68% of revenue in 2012. The drug is patent protected until 2024 in the EU and 2027 in the U.S.

Celgene Corporation (NASDAQ:CELG) is up 40% since my favorable article on January 7. In March, I wrote, “5 Reasons Celgene Remains a Long-Term Buy.” Those reasons, which still hold true, are:

  1. Highly innovative management
  2. No big patent cliffs approaching
  3. Strong late-stage pipeline
  4. Solid metrics
  5. Reasonable valuation
Page 1 of 2
Loading Comments...